Maximale Androgenblockade: Metaanalyse und kein Ende

Aktuelle Urologie

Volumn 28, Issue 3, 1997, Pages 129-132

  Altwein, J E ^a  

^a Urologische Abteilung des Krankenhauses der Barmherzigen Brüder   (Germany)

Author keywords

Metaanalysis; Prostate cancer

Indexed keywords

EID: 21744443030     PISSN: 00017868     EISSN: 14388820     Source Type: Journal    
DOI: 10.1055/s-2008-1054262     Document Type: Editorial

References (22)

1. Altwein, J. E., J. Silchinger: An assessment of maximal androgen blockade in the treatment of advanced prostatic carcinoma. Onkologie 19 (1996) 302-307
2. Bennett, C. L., D. Matchar, D. McCrory, D. G. McLeod, E. D. Crawford, B. E. Hillner: Cost-effective models for flutamide for prostate carcinoma patients. Are they helpful to policy makers? Cancer 77 (1996) 1854-1861
3. Bertagna, C, A. de Géry, M. Hucher, J. P. Francois, J. Zanirato: Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients). Br. J. Urol. 73 (1994) 396-402
4. Caubet, J. F., T. D. Tosteson, E. W. Dong, E. M. Naylon, G. W. Whiting, M. S. Ernstoff, S. D. Ross: Maximum androgen blockade in advanced prostate cancer: A meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 49 (1997) 71-78
5. Chalmers, T. C., H. Smith, B. Blackbush, B. Silverman, B. Schröder, D. Reitman, A. Ambroz: A method for assessing the quality of a randomized control trial. Controlled Clin. Trials, 2 (1981) 31-49
6. Crawford, E. D., M. A. Eisenberger, D. G. McLeod, J. T. Spaulding, R. Benson, F. A. Dorr, B. A. Blumenstein, M. A. Davis, P.J. Goodman: A controlled trial of leuprolide with an without flutamide in prostatic carcinoma. N. Engl. J. Med. 321 (1989) 419-424
7. Crawford, E. D., E. P. De Antoni: Combined androgen blockade: An idea whose time has come. In Murphy, G., S. Khoury, S. Chatelain, L. Denis (Hrsg.): Recent advances in urological cancer - diagnosis and treatment. Scientific Communication International. Jersey 1993, pp. 260-268
8. Crawford, E. D., E. P. De Antonio, F. Labrie, F. Schroder, J. Geller: Therapeutic controversies. Endocrine therapy of prostate cancer: optimal form and appropriate timing. J. Clin. Endocrinol. Metabol. 80 (1995) 1062-1078
9. Dalesio, O.: Complete androgen blockade: organizing an overview. Cancer 66 (1990) 1080-1082
10. Denis, J. L., P. Whelan, J. L. Carneiro de Moura, D. Newling et al.: Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). Urology 42 (1993) 119-130
11. Jörgensen, T., K. J. Tveter, L. H. Jörgensen: Total androgen suppresison: experience from the Scandinavian Prostate Cancer Group Study No.2. Eur. Urol. 24 (1993) 466-470
12. Klotz, L. H., T. Newman: Does maximal androgen blockade (MAB) improve survival? A critical appraisal of the evidence. Canad. J. Urol. 3 (1996) 246-250
13. Knönagel, A., F. F. Bolle, F. Hering, E. Senn, T. H. Hockl, H. Neuenschwander, C. Biedermann: Die Therapie des metastasierten Prostatakarzinoms durch Orchiektomie plus Anandron versus Orchiektomie plus Plazebo: Erste Ergebnisse einer randomisierten Multizenterstudie. Helv. Chir. Acta 56 (1989) 343-345
14. Kuhn, J.-M., T. Billebaud, H. Navratil, A. Moulonguet, J. Fiet, P. Grise, J. F. Lonis, P. Costa, J.-M. Hausson, R. Dahan, C. Bertagna, R. Edelstein: Prevention of the transient adverse effects of a gonadotrophin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N. Engl. J. Med. 321 (1989) 413-418
15. Labrie, F., D. Crawford: Letters to the Editor. Anti-androgens in treatment of prostate cancer. Lancet 346 (1994) 1030-1031
16. Meyer, T. J., M. M. Mark: Effects of psychosocial interventions with adult cancer patients: A metaanalysis of randomized experiments. Health Psychol. 14 (1995) 101-108
17. Moher, D., P. Fortin, A. R. Jadad, P. Jüni, T. Klassen, J. Le Lorier, A. Liberati, K. Linde: Completeness of reporting of trials published in languages other than English: implications for conduct and reporting of systematic reviews. Lancet 347 (1996) 363-366
18. Prostate Cancer Trialist's Collaborative Group: Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 346 (1995) 265-269
19. Schröder, F. H.: Endocrine therapy for prostate cancer: Recent developments and current status. Br. J. Urol. 71 (1993) 633-640
20. Smith, P. H.: The case against total androgen ablation in the management of metastatic prostate cancer. In Murphy, G., S. Khoury, C. Chatelain, L. Denis (Hrsg.): Recent advances in urological cancer. Diagnosis and treatment. Scientific Communication International. Jersey 1993, pp. 269-272
21. Studer, U. E.: Fortgeschrittenes Prostatakarzinom - welche Hormontherapie wann? Urologe A 34 (1995) 361-366
22. Waxman, J.: Letters to the Editor. Anti-androgens in treatment of prostate cancer. Lancet 346 (1994) 1030-1031